Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enzastaurin for prevention of arterial events in vascular Ehlers-Danlos syndrome
NL-OMON51515Phase 3Withdrawn
- Sponsor
- Aytu BioPharma
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Vascular Ehlers-Danlos syndrome (VEDS) comparing Enzastaurin + standard of care with Placebo + standard of care (2 arms). Primary endpoint: Time to intervention for an arterial event or arterial event-related mortality. Planned start Apr 2022; status: withdrawn.
02
Drugs
enzastaurin
03
Conditions
Vascular Ehlers-Danlos syndrome (VEDS)
Beyond the preview
Go deeper on NL-OMON51515.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51515.